Cargando…

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer

ABSTRACT: PURPOSE: Clinical Treatment Score at 5 years (CTS5) is a prognostic tool to estimate distant recurrence (DR) risk after 5 years of endocrine therapy for postmenopausal women with oestrogen receptor-positive (ER-positive) breast cancer. METHODS: The validity of CTS5 was tested in a retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richman, Juliet, Ring, Alistair, Dowsett, Mitch, Sestak, Ivana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940308/ https://www.ncbi.nlm.nih.gov/pubmed/33222093 http://dx.doi.org/10.1007/s10549-020-06013-6

Ejemplares similares

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
por: Sestak, Ivana, et al.
Publicado: (2016)

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
por: Sestak, Ivana, et al.
Publicado: (2013)

Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction
por: Wang, Changjun, et al.
Publicado: (2022)

The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
por: Tajiri, Wakako, et al.
Publicado: (2020)

Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer
por: Haynes, Ben P., et al.
Publicado: (2021)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Markers for the identification of late breast cancer recurrence
por: Sestak, Ivana, et al.
Publicado: (2015)

CTS Trials Network: A paradigm shift in the surgical treatment of moderate ischemic mitral regurgitation?
por: Afifi, Ahmed
Publicado: (2015)

Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life
por: Wyld, Lynda, et al.
Publicado: (2021)

Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2020)

CTS Trials Network: Surgical ablation of atrial fibrillation during mitral valve surgery - many questions unanswered
por: Afifi, Ahmed
Publicado: (2015)

Clinical Utility of the 6-Item CTS, Boston-CTS, and Hand-Diagram for Carpal Tunnel Syndrome
por: Schulze, Daniel Gregor, et al.
Publicado: (2021)

BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer
por: Nilsson, Martin P., et al.
Publicado: (2017)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
por: Cuzick, Jack, et al.
Publicado: (2013)

Author Correction: Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2021)

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
por: Sheri, A., et al.
Publicado: (2017)

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
por: Hale, Michael J., et al.
Publicado: (2020)

Clinical Utility of Boston-CTS and Six-Item CTS Questionnaires in Carpal Tunnel Syndrome Associated with Diabetic Polyneuropathy
por: Drăghici, Nicu Cătălin, et al.
Publicado: (2022)

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study
por: Yeo, B, et al.
Publicado: (2015)

Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients
por: Villasco, Andrea, et al.
Publicado: (2021)

CTS trials network: Rate control vs rhythm control for atrial fibrillation after cardiac surgery - Do bitter pills have blessed effects?
por: Afifi, Ahmed
Publicado: (2016)

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
por: Stemmer, Salomon M., et al.
Publicado: (2013)

MD-CTS: An integrated terminology reference of clinical and translational medicine
por: Ray, Will, et al.
Publicado: (2016)

CTS Technical Days
por: Commission of the European Communities. Brussels. Telecommunications, Information Industries and Innovation
Publicado: (1987)

Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza
por: Landry, Nathalie, et al.
Publicado: (2010)

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers
por: Ribas, Ricardo, et al.
Publicado: (2014)

Omnidirectional 2.5D representation for COVID-19 diagnosis using chest CTs()
por: da Silveira, Thiago L.T., et al.
Publicado: (2023)

Ultra‐hypofractionated radiation therapy for unfavourable intermediate‐risk and high‐risk prostate cancer is safe and effective: 5‐year outcomes of a phase II trial
por: Macias, Victor A., et al.
Publicado: (2019)

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
por: Gellert, Pascal, et al.
Publicado: (2016)

A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone
por: Rakovitch, Eileen, et al.
Publicado: (2015)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Oestrogens Downregulate Tissue Factor Pathway Inhibitor through Oestrogen Response Elements in the 5’-Flanking Region
por: Ali, Huda Omar, et al.
Publicado: (2016)

Are Unselected Risk Scores in the Cardiac Intensive Care Unit Needed?
por: Miller, P. Elliott, et al.
Publicado: (2021)

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Sestak, Ivana, et al.
Publicado: (2018)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence
por: Kruis, W., et al.
Publicado: (2017)

Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer
por: Ueda, Hiroto, et al.
Publicado: (2018)

Progress with the CLIC transfer structures (CTS)
por: Carron, G, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_0sfi7hts2dgmauu3km0ntqfdm2